Dr. Davis on the ANZUP Collaboration on the ENZAMET Trial in Prostate Cancer

Ian Davis, MBBS, PhD, FRACP, FAChPM
Published: Tuesday, Sep 10, 2019





Ian Davis, MBBS, PhD, FRACP, FAChPM, professor of medicine at Monash University and Eastern Health, and head of the Eastern Health Clinical School, discusses the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) collaboration on the randomizedphase III ENZAMET trial (NCT02446405) in metastatic hormone-sensitive prostate cancer (mHSPC).
 
With over 1500 members, ANZUP is a cooperative cancer trials group aimed at targeting all aspects of the care and research of urogenital and prostate cancer across Australia, New Zealand, and internationally, explains Davis.
 
The ENZAMET trial evaluated the addition of enzalutamide (Xtandi) to androgen-deprivation therapy in the frontline treatment of patients with mHSPC. The trial was organized by the University of Sydney and the NHMRC Clinical Trials Center. Along with ANZUP, the lead research organization, Cancer Trials Ireland, the Canadian Cancer Trials Group, and Dana-Farber Cancer Institute partnered on the ENZAMET trial.
 
An important outcome of this trial, aside from the favorable clinical data showing a decrease in mortality with enzalutamide, is the global organization of networks and future collaboration between these groups, says Davis.
SELECTED
LANGUAGE




Ian Davis, MBBS, PhD, FRACP, FAChPM, professor of medicine at Monash University and Eastern Health, and head of the Eastern Health Clinical School, discusses the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) collaboration on the randomizedphase III ENZAMET trial (NCT02446405) in metastatic hormone-sensitive prostate cancer (mHSPC).
 
With over 1500 members, ANZUP is a cooperative cancer trials group aimed at targeting all aspects of the care and research of urogenital and prostate cancer across Australia, New Zealand, and internationally, explains Davis.
 
The ENZAMET trial evaluated the addition of enzalutamide (Xtandi) to androgen-deprivation therapy in the frontline treatment of patients with mHSPC. The trial was organized by the University of Sydney and the NHMRC Clinical Trials Center. Along with ANZUP, the lead research organization, Cancer Trials Ireland, the Canadian Cancer Trials Group, and Dana-Farber Cancer Institute partnered on the ENZAMET trial.
 
An important outcome of this trial, aside from the favorable clinical data showing a decrease in mortality with enzalutamide, is the global organization of networks and future collaboration between these groups, says Davis.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 3rd Annual International Congress on Oncology & Pathology™Aug 30, 20201.5
Community Practice Connections™: ASCO Direct™ Highlights – 2019 Official Annual Meeting ReviewAug 30, 20201.5
Publication Bottom Border
Border Publication
x